Eupraxia Pharmaceuticals reported fourth quarter 2025 results, pairing positive clinical signals from its eosinophilic esophagitis program with strengthened finances....

Tonix Pharmaceuticals has turned the corner from development to commercialization with the U.S. launch of Tonmya, a sublingual cyclobenzaprine...

Korro Bio has nominated KRRO-121 as its next clinical candidate for the treatment of hyperammonemia in urea cycle disorders...

Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...

Lyell Immunopharma has begun dosing in a first-of-its-kind phase 3 head-to-head randomized trial in second-line large B-cell lymphoma, testing...

Bolt Biotherapeutics reported 2025 results and advanced its first-in-class immune-stimulating antibody conjugate, BDC-4182, into a Phase 1 dose-escalation study...

Vaxart reported a pivotal business update: enrollment is complete in its approximately 5,400-participant phase 2b COVID-19 trial comparing an...

Allogene Therapeutics has set two near-term catalysts that could redefine where and how cell therapy is used: an April...

Corvus Pharmaceuticals reported positive cohort 4 results from its randomized, blinded phase 1 trial of soquelitinib in moderate-to-severe atopic...

ProQR Therapeutics reported year-end 2025 results and a business update centered on advancing its Axiomer RNA editing platform. The...